Direct pressure for 5 minutes reduces ecchymosis after venipuncture in older anticoagulated patients
How long should you press after a blood draw to prevent bruising in older adults?
A randomized controlled trial of 164 older hospitalized patients on anticoagulants found that applying 20 N of direct pressure for 5 minutes…
Holding pressure for five minutes after a blood draw significantly reduces painful bruises in older adults taking blood thinners compared to…
Systematic review shows increased fat mass and decreased fat-free mass in children with acute lymphoblastic leukemia during treatment.
ALL Treatment Linked to Changes in Body Fat and Muscle in Young Patients
This systematic review and meta-analysis of 13 studies examined body composition changes in children and young people aged 0-21 years with a…
ALL treatment causes early fat gain and muscle loss in young patients that often persists long after therapy ends.
Phase II trial shows high remission and survival with frontline ATRA-ATO for newly diagnosed APL
Can a chemotherapy-free treatment beat a rare, aggressive leukemia?
A prospective multicenter phase II trial in 81 newly diagnosed APL patients in Japan found that frontline ATRA-ATO therapy achieved a 95.1% …
A chemotherapy-free treatment for acute promyelocytic leukemia achieved 95% remission and 95% survival three years later in a Japanese trial…
Systematic review explores necroptosis as a therapeutic target in multiple myeloma
Could a different kind of cell death help treat stubborn blood cancer?
A systematic review integrates current evidence on necroptosis in multiple myeloma. It reports that necroptosis-associated genes influence p…
When standard treatments fail, triggering a different cell death process called necroptosis might kill resistant cancer cells and boost the …
Observational study explores daratumumab resistance mechanisms in primary light-chain amyloidosis
Small study links daratumumab resistance to immune changes in light-chain amyloidosis
An observational cohort study of 30 patients with primary light-chain amyloidosis treated with daratumumab-bortezomib-dexamethasone found th…
Patients with weaker responses to amyloidosis treatment showed lower gene activity before therapy and increased immune stress during treatme…
Point-of-care hemoglobin meters show high sensitivity but lower specificity versus analyzer in Ghanaian study
Study finds portable anemia meters may underestimate hemoglobin levels compared to lab tests
A cross-sectional study of 100 laboratory visitors in Kumasi, Ghana compared point-of-care hemoglobin meters (Urit and Mission) to an automa…
Portable anemia meters flagged every true case but also mislabeled many healthy people as anemic, underestimating hemoglobin levels by about…
Gene therapy reduces bleeding rates and factor use in adults with severe hemophilia A
Can gene therapy reduce bleeding and treatment burden for adults with severe hemophilia A?
A systematic review and meta-analysis of adults with severe/moderately severe hemophilia A found gene therapy reduced annualized bleeding ra…
For adults with severe hemophilia A, gene therapy may offer a way to bleed less and rely far less on regular infusions. A review of existing…
CellSearch CMMC assay shows analytical sensitivity for non-invasive MRD monitoring in multiple myeloma
Could a simple blood test replace painful bone marrow biopsies for myeloma monitoring?
A study of unspecified design evaluated the analytical performance of the CellSearch CMMC assay for minimal residual disease monitoring in m…
A new blood test can detect single cancer cells left after multiple myeloma treatment, offering a less invasive way to monitor disease level…
Phase 1b trial finds tafasitamab combinations manageable in Japanese B-cell NHL patients
Early study tests tafasitamab alone and in combinations for Japanese lymphoma patients
A phase 1b trial in 24 Japanese patients with relapsed/refractory or untreated B-cell NHL assessed tafasitamab alone or in combination. All …
Japanese lymphoma patients received new drug tafasitamab alone or with others, showing manageable side effects like low blood counts and nau…
Phase 3 trial of damoctocog alfa pegol in previously treated children with severe haemophilia A
Phase 3 trial studies new treatment for severe haemophilia A in children
A phase 3 clinical trial evaluated damoctocog alfa pegol in previously treated children aged 7 to 12 years with severe haemophilia A. No res…
A new treatment for severe haemophilia A in children aged 7 to 12 is being tested in a Phase 3 trial to check its safety and effectiveness.
Damoctocog alfa pegol shows safety and maintained bleed protection in children with severe haemophilia A
Study finds haemophilia drug safe and effective in children over six months
A phase 3, open-label, single-arm study of 35 previously treated children aged 7 to <12 years with severe haemophilia A found no adverse eve…
A haemophilia drug prevented bleeds in children aged 7 to under 12, with no severe side effects and no one stopping treatment due to bad rea…
Case report describes likely first autochthonous Chagas disease case in Missouri blood donor
Blood donor in Missouri tests positive for Chagas disease, likely first local case
A case report describes a blood donor in Missouri with a positive screening result for Trypanosoma cruzi antibodies. The authors classify th…
A Missouri blood donor likely represents the first local case of Chagas disease, a parasite usually found in Latin America.